Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis

Egyptian Rheumatology and Rehabilitation

Table 8 Correlation between the WBCs, RBCs, and Plptelets indices with duration of biologic therapy

AS	Duration biologics (months)
	r	P value
WBCS	− 0.030	0.879
Neutrophils	− 0.041	0.834
Lymphocytes	− 0.091	0.643
HCT	0.007	0.973
RBCs	0.102	0.604
Hb	− 0.008	0.967
MCV	− 0.143	0.468
MCH	0.138	0.483
RDW%	0.109	0.581
PLT	− 0.050	0.799
MPV/fl	0.341	0.076
PWD	0.230	0.239
Hb/PLT ratio	0.018	0.928
RDW%/PLT ratio	0.021	0.914
RBCs/PLT ratio	0.133	0.501
Hb/RDW% ratio	− 0.057	0.773
Neutrophil/lymphocyte ratio	0.096	0.626
PLT/lymphocyte ratio	0.015	0.939

AS ankylosing spondylitis, DD disease duration, WBCs white blood cells, Neut. neutrophils, HCT hematocrit, RBCs red blood cells, HB hemoglobin, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, RDW red cell distribution width, PLT platelet, MPV mean platelet volume, PDW platelet distribution width, Lympho lymphocyte, SD standard deviation. Level of significance: P ≤ 0.05: Significant, P < 0.005: highly significant